Servier completed its acquisition of Day One Biopharmaceuticals and its buyout of Edgewise Therapeutics’ neuromuscular business is expected to close later this year. At the BIO International Convention, Servier’s top business development executive explained the rationale for these deals and how they fit the company’s overall strategy.
The post Servier Executive: ‘We Are Not Looking for Blockbusters, We’re Looking for Innovative Science’ appeared first on MedCity News.
